NCT01936389View on ClinicalTrials.gov

A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
Exfoliation SyndromeOcular HypertensionOpen Angle Glaucoma
Interventions
DRUG

AR-12286

Trial Locations (1)

10003

Glaucoma Associates of New York, New York

All Listed Sponsors
lead

Robert Ritch, MD, LLC.

OTHER

NCT01936389 - A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma | Biotech Hunter | Biotech Hunter